Mizuki Nishino1, Stephanie Cardarella2, Suzanne E Dahlberg3, Tetsuro Araki4, Christine Lydon2, David M Jackman2, Michael S Rabin2, Hiroto Hatabu4, Bruce E Johnson2. 1. Department of Radiology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA; Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Electronic address: Mizuki_Nishino@DFCI.HARVARD.EDU. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215. 3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. 4. Department of Radiology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA.
Abstract
OBJECTIVE: Interstitial lung diseases are associated with increased risk of lung cancer. The prevalence of ILA at diagnosis of advanced non-small-cell lung cancer (NSCLC) and its impact on overall survival (OS) remain to be investigated. MATERIALS AND METHOD: The study included 120 treatment-naïve stage IV NSCLC patients (53 males, 67 females). ILA was scored on CT prior to any systemic therapy using a 4-point scale [0=no evidence of ILA, 1=equivocal for ILA, 2=suspicious for ILA, 3=ILA] by a sequential reading method previously reported. ILA scores of 2 or 3 indicated the presence of ILA. RESULTS: ILA was present in 17 patients (14%) with advanced NSCLC prior to any treatment (score3: n=2, score2: n=15). These 17 patients were significantly older (median age: 69 vs. 63, p=0.04) and had a heavier smoking history (median: 40 vs. 15.5 pack-year, p=0.003) than those with ILA score 0 or 1. Higher ILA scores were associated with shorter OS (p=0.001). Median OS of the 17 patients with ILA was 7.2 months [95%CI: 2.9-9.4] compared to 14.8 months [95%CI: 11.1-18.4] in patients with ILA score 0 or 1 (p=0.002). In a multivariate model, the presence of ILA remained significant for increased risk for death (HR=2.09, p=0.028) after adjusting for first-line systemic therapy (chemotherapy, p<0.001; TKI, p<0.001; each compared to no therapy) and pack years of smoking (p=0.40). CONCLUSION: Radiographic ILA was present in 14% of treatment-naïve advanced NSCLC patients. Higher ILA scores were associated with shorter OS, indicating that ILA could be a marker of shorter survival in advanced NSCLC.
OBJECTIVE:Interstitial lung diseases are associated with increased risk of lung cancer. The prevalence of ILA at diagnosis of advanced non-small-cell lung cancer (NSCLC) and its impact on overall survival (OS) remain to be investigated. MATERIALS AND METHOD: The study included 120 treatment-naïve stage IV NSCLCpatients (53 males, 67 females). ILA was scored on CT prior to any systemic therapy using a 4-point scale [0=no evidence of ILA, 1=equivocal for ILA, 2=suspicious for ILA, 3=ILA] by a sequential reading method previously reported. ILA scores of 2 or 3 indicated the presence of ILA. RESULTS: ILA was present in 17 patients (14%) with advanced NSCLC prior to any treatment (score3: n=2, score2: n=15). These 17 patients were significantly older (median age: 69 vs. 63, p=0.04) and had a heavier smoking history (median: 40 vs. 15.5 pack-year, p=0.003) than those with ILA score 0 or 1. Higher ILA scores were associated with shorter OS (p=0.001). Median OS of the 17 patients with ILA was 7.2 months [95%CI: 2.9-9.4] compared to 14.8 months [95%CI: 11.1-18.4] in patients with ILA score 0 or 1 (p=0.002). In a multivariate model, the presence of ILA remained significant for increased risk for death (HR=2.09, p=0.028) after adjusting for first-line systemic therapy (chemotherapy, p<0.001; TKI, p<0.001; each compared to no therapy) and pack years of smoking (p=0.40). CONCLUSION: Radiographic ILA was present in 14% of treatment-naïve advanced NSCLCpatients. Higher ILA scores were associated with shorter OS, indicating that ILA could be a marker of shorter survival in advanced NSCLC.
Authors: Tracy J Doyle; George R Washko; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; Miguel J Divo; Bartolome R Celli; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas; Gary M Hunninghake Journal: Am J Respir Crit Care Med Date: 2012-01-20 Impact factor: 21.405
Authors: Yelena Y Janjigian; Kevin McDonnell; Mark G Kris; Ronglai Shen; Camelia S Sima; Peter B Bach; Naiyer A Rizvi; Gregory J Riely Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Marie-Christine Aubry; Jeffrey L Myers; William W Douglas; Henry D Tazelaar; Tanya L Washington Stephens; Thomas E Hartman; Claude Deschamps; V Shane Pankratz Journal: Mayo Clin Proc Date: 2002-08 Impact factor: 7.616
Authors: Mizuki Nishino; Emily S Chambers; Curtis R Chong; Nikhil H Ramaiya; Stacy W Gray; J Paul Marcoux; Hiroto Hatabu; Pasi A Jänne; F Stephen Hodi; Mark M Awad Journal: Cancer Immunol Res Date: 2016-02-10 Impact factor: 11.151
Authors: Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake Journal: Am J Respir Crit Care Med Date: 2019-07-15 Impact factor: 21.405
Authors: Hiroto Hatabu; Gary M Hunninghake; Luca Richeldi; Kevin K Brown; Athol U Wells; Martine Remy-Jardin; Johny Verschakelen; Andrew G Nicholson; Mary B Beasley; David C Christiani; Raúl San José Estépar; Joon Beom Seo; Takeshi Johkoh; Nicola Sverzellati; Christopher J Ryerson; R Graham Barr; Jin Mo Goo; John H M Austin; Charles A Powell; Kyung Soo Lee; Yoshikazu Inoue; David A Lynch Journal: Lancet Respir Med Date: 2020-07 Impact factor: 30.700
Authors: Sree Harsha Tirumani; Nikhil H Ramaiya; Abhishek Keraliya; Nancy D Bailey; Patrick A Ott; F Stephen Hodi; Mizuki Nishino Journal: Cancer Immunol Res Date: 2015-06-22 Impact factor: 11.151
Authors: Won Gi Jeong; Yun-Hyeon Kim; Jong Eun Lee; In-Jae Oh; Sang Yun Song; Kum Ju Chae; Hye Mi Park Journal: Cancer Res Treat Date: 2021-09-28 Impact factor: 5.036
Authors: Mizuki Nishino; Lauren K Brais; Nichole V Brooks; Hiroto Hatabu; Matthew H Kulke; Nikhil H Ramaiya Journal: Eur J Cancer Date: 2016-01-04 Impact factor: 9.162